Monoceros Biosystems, a leading bioinformatics/computational biology provider, is pleased to announce the appointment of Jonathan Spier to its Board of Directors
We are delighted to announce the appointment of Jonathan [...]
Monoceros Biosystems, a leading bioinformatics/computational biology provider, is pleased to announce the appointment of Regan Lohman to its Board of Directors
We are thrilled to announce the appointment of Regan Lohman [...]
Monoceros Biosystems and SeekIn Join Forces to Pave the Way for Cutting-Edge AI-Powered Cancer Diagnostics
San Diego, September 21, 2023 – Monoceros Biosystems, a prominent [...]
MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Mirati Therapeutics, in collaboration with Monoceros Biosystems and leading academic [...]
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Mirati Therapeutics, in collaboration with Array BioPharma (Pfizer) and Monoceros [...]
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Mirati Therapeutics, in collaboration with additional groups including Monoceros Biosystems, [...]
Monoceros Biosystems: Bringing Professional Grade Bioinformatics to All
Monoceros Biosystems has been selected as a top 10 bioinformatics [...]